The BD Alaris infusion set FDA alert has a supply-chain dimension that goes beyond the infusion pump itself: the affected sets are packed inside Cardinal Health Presource convenience kits, which means a recall of one component reaches hospitals through a kit supplier and, in some cases, through distributors. The FDA published two early alerts on 20 October 2026, and one of them tells distributors that passed on affected kits to notify their customers.
Key takeaways: the BD Alaris infusion set FDA alert and the kit supply chain
- The FDA early alerts concern Cardinal Health Presource kits that contain BD Alaris pump infusion sets affected by a BD and CareFusion 303 recall.
- Cardinal Health recommends locating and quarantining affected kits, alerting clinicians, and labelling kits to remove and discard the recalled components.
- Distributors that further distributed kits should notify their customers, according to the FDA.
- BD had reported no serious injuries or deaths as of 19 August 2026.
- The FDA is still reviewing the issue and will update its pages.
How convenience kits complicate the BD Alaris infusion set FDA alert
A convenience kit bundles several items for a procedure or care task. If one item is recalled, the kit may need to be corrected even though the other items are fine. The FDA’s correction alert says Cardinal Health has asked customers to correct all kits containing affected infusion sets before continued use, by removing and discarding the recalled components after labelling the kit. The text does not say how replacement sets will be supplied. The two FDA pages are here and here.
What went wrong in the BD Alaris infusion set FDA alert
The FDA says BD’s continued testing found that previously claimed infusion performance was overestimated for some sets, and in some cases significantly worse. The deviations are most common at rates under 1 mL per hour and at boluses of 5 mL or less, and they can lead to under-infusion, over-infusion, delayed occlusion alarms or inaccurate bolus delivery. The sets contain restrictive components, including closed male luer connectors, filters, check valves, Y-sites and microbore tubing. The FDA says the risk is higher for neonates, paediatric patients and critically ill patients.
Why low-rate infusions are the focus of the BD Alaris infusion set FDA alert
At low flow rates, small absolute errors are large in proportion to the intended dose. The FDA gives antiarrhythmics and blood-pressure support medicines as examples of drugs often given at low rates or small volumes to high-risk patients. For a supply team, this means that not every kit carries the same clinical risk: kits used in neonatal and intensive-care units may need priority. That prioritisation is our suggestion based on the FDA’s risk description and is not an FDA instruction.
Timeline for procurement teams after the BD Alaris infusion set FDA alert
- 19 August 2026: BD US customer letter; BD’s no-serious-injury statement is current as of this date.
- September 2026: Cardinal Health customer letter; the two alerts give 23 and 24 September, and we flag this difference and do not choose between them.
- 5 October 2026: recall notice date listed by the FDA.
- 20 October 2026: FDA early alerts published.
Questions procurement and supply teams may ask
The questions below are our own, based on general supply-chain practice, and are not drawn from the FDA, BD or Cardinal Health:
- Which kit catalogue numbers contain affected sets, and how many are on hand?
- Were any kits passed on to satellite sites, clinics or other departments?
- How will replacement kits or sets be sourced, and on what timeline?
- Who documents quarantine, labelling and discard?
- Do clinicians in neonatal and intensive-care units know which alternative pump options are available?
The FDA’s own advice, for clinical use, is to review BD’s performance disclosures and adjust set selection or pump use as needed, to consider an alternative such as the BD Alaris Syringe Module or another syringe pump, and, if none is available, to use the sets with caution and enhanced monitoring.
General background: why recalls of components are hard to manage
When a component is built into a kit, the end user may not know it is there. Tracking depends on lot and catalogue numbers, supplier communication and the hospital’s own inventory systems. Delays in any link can leave affected items on shelves. Adverse events and quality problems can be reported to the FDA’s MedWatch program. See also our medical devices coverage.
Our analysis: what the BD Alaris infusion set FDA alert shows about device safety
In our assessment, the BD Alaris infusion set FDA alert shows how a performance issue in one component can travel through a supply chain. It also shows the value of early alerts: the FDA published this one while still reviewing the issue, giving hospitals time to act. The alert is limited in scope, and it does not say that every BD Alaris product is affected.
We have no data on how many kits are in hospitals, how many have been corrected or how long replacements will take. We also make no financial or commercial claims about BD or Cardinal Health.
What is not disclosed about the BD Alaris infusion set FDA alert
- Kit names and catalogue numbers in the alert text.
- The number of kits and sets in distribution.
- Replacement timelines.
- Any injuries or deaths after 19 August 2026.
- The root cause analysis.
Risks and caveats of the BD Alaris infusion set FDA alert
This article is based on the FDA’s two early alerts, which the agency may update. We have not seen BD’s customer letters or Cardinal Health’s notices. This is news reporting and not clinical, procurement or legal advice.
What to watch next after the BD Alaris infusion set FDA alert
- Updates to the FDA alerts.
- Replacement kit availability from Cardinal Health.
- Any further recall notices from BD.
- Hospital reports of corrected kits.
FAQ
Why are kits involved in the BD Alaris infusion set FDA alert?
The affected infusion sets are packed inside Cardinal Health Presource kits, so the kits need to be corrected.
What should distributors do?
The FDA says distributors that further distributed affected kits should notify their customers.
Are injuries reported?
BD reported no serious injuries or deaths as of 19 August 2026.
How we reported this: we relied on the two FDA early alerts and attributed every instruction and risk statement to them. Last updated 23 October 2026. This is news reporting and not advice.
